
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
European Union-The European Commission’s ban on GlaxoSmith–Kline’s dual pricing policy in Spain halts one of Big Pharma’s attempts to prevent parallel imports in Europe.
over 25 years ago
Pharmacies: OTC Price Warsover 25 years ago
One Disease at a Timeover 25 years ago
Overview of the Industry: A World of Opportunitiesover 25 years ago
The Power Shiftover 25 years ago
A Giant Stumblesover 25 years ago
Submergedover 25 years ago
Generic Threat





